Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma

Pathology Research and Practice

Volumn 210, Issue 1, 2014, Pages 30-34

  Selemetjev, Sonja ^a   Dencic, Tijana Isic ^a   Marecko, Ilona ^a   Jankovic, Jelena ^a   Paunovic, Ivan ^b   Savin, Svetlana ^a   Cvejic, Dubravka ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Lymph node metastasis; Papillary thyroid carcinoma; Prognosis; Survivin; Tumor stage

Indexed keywords

SURVIVIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PROTEIN EXPRESSION; THYROID CARCINOMA; TUMOR INVASION; VERY ELDERLY; WESTERN BLOTTING;

LYMPH NODE METASTASIS; PAPILLARY THYROID CARCINOMA; PROGNOSIS; SURVIVIN; TUMOR STAGE;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84891493258     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.09.014     Document Type: Article

References (32)

1. LiVolsi V.A., Albores-Saavedra J., Asa S.L., et al. Papillary carcinoma. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Endocrine Organs 2004, 57-66. IARC Press, Lyon, France. R. De Lellis, R. Lloyd, P.U. Heitz, C. Eng (Eds.).
2. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural history, treatment, and course of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 1990, 71:414-424.
3. Mazzaferri E.L., Young R.L. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am. J. Med. 1981, 70:511-518.
4. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from surveillance, epidemiology and END results (SEER) program 1973-1991. Cancer 1997, 79:564-573.
5. Siironen P., Louhimo J., Nordling S., Ristimäki A., Mäenpää H., Haapiainen R., Haglund C. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol. 2005, 26:57-64.
6. Ito Y., Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr. J. 2009, 56:177-192.
7. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
8. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999, 13:239-252.
9. Yang Y.L., Li X.M. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res. 2000, 10:169-177.
10. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
11. Li F., Altieri D.C. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res. 1999, 59:3143-3151.
12. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by surviving. Nature 1998, 396:580-584.
13. Mita A.C., Mita M.M., Nawrocki S.T., Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14:5000-5005.
14. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010, 430:199-205.
15. Blanc-Brude O.P., Mesri M., Wall N.R., Plescia J., Dohi T., Altieri D.C. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin. Cancer Res. 2003, 9:2683-2692.
16. Waligórska-Stachura J., Jankowska A., Waśko R., Liebert W., Biczysko M., Czarnywojtek A., Baszko-Błaszyk D., Shimek V., Ruchala M. Survivin-prognostic tumor biomarker in human neoplasms - review. Ginekol. Pol. 2012, 83:537-540.
17. Tirrò E., Consoli M.L., Massimino M., Manzella L., Frasca F., Sciacca L., Vicari L., Stassi G., Messina L., Messina A., Vigneri P. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res. 2006, 66:4263-4272.
18. Antonaci A., Consorti F., Mardente S., Natalizi S., Giovannone G., Della Rocca C. Survivin and cyclin D1 are jointly expressed in thyroid papillary carcinoma and microcarcinoma. Oncol. Rep. 2008, 20:63-67.
19. Ito Y., Yoshida H., Uruno T., Nakano K., Miya A., Kobayashi K., Yokozawa T., Matsuzuka F., Matsuura N., Kakudo K., Kuma K., Miyaushi A. Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma. Oncol. Rep. 2003, 10:1337-1340.
20. Zhang H.Y., Meng X., Du Z.X., Fang C.Q., Liu G.L., Wang H.Q., Deng W.W. Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma. Clin. Exp. Med. 2009, 9:207-213.
21. Chen Z., Liu N., Zhu G., Dralle H., Hoang-Vu C. Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma. Int. J. Mol. Med. 2012, 30:465-472.
22. Kim Y.A., Chang M., Park Y.J., Kim Y.E. Detection of survivin and COX-2 in thyroid carcinoma: anaplastic carcinoma shows overexpression of nuclear survivin and low COX-2 expression. Korean J. Pathol. 2012, 46:55-60.
23. Wang Y.X., Li M.L., Yu S.G., Liu C.M., Han Y., Wang X.Y. The association between the Survivin A9194G exon polymorphisms and papillary thyroid carcinoma risk in the Han Chinese population. Pathol. Res. Pract. 2013, 209:151-154.
24. World Health Organization Classification of Tumours. Pathology and genetics of tumours of endocrine organs 2004, 54-55. IARC Press, Lyon. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (Eds.).
25. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors 2002, Wiley-Liss, New York. 6th ed. L.H. Sobin, C. Wittekind (Eds.).
26. Brennan D.J., Rexhepaj E., O'Brien S.L., McSherry E., O'Connor D.P., Fagan A., Culhane A.C., Higgins D.G., Jirstrom K., Millikan R.C., Landberg G., Duffy M.J., Hewitt S.M., Gallagher W.M. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin. Cancer Res. 2008, 14:2681-2689.
27. Li F., Yang J., Ramnath N., Javle M.M., Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance?. Int. J. Cancer 2005, 114:509-512.
28. Stauber R.H., Mann W., Knauer S.K. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007, 67:5999-6002.
29. Yoshida A., Nakamura Y., Imada T., Asaqa T., Shimizu A., Harada M. Apoptosis and proliferative activity in thyroid tumors. Surg. Today 1999, 29:204-208.
30. Cvejic D., Selemetjev S., Savin S., Paunovic I., Tatic S. Changes in the balance between proliferation and apoptosis during the progression of malignancy in thyroid tumours. Eur. J. Histochem. 2009, 53:65-71.
31. Clark O.H. Thyroid cancer and lymph node metastases. J. Surg. Oncol. 2011, 103:615-618.
32. Mehrotra S., Languino L.R., Raskett C.M., Mercurio A.M., Dohi T., Altieri D.C. IAP regulation of metastasis. Cancer Cell 2010, 17:53-77.